BRISTOL-MYERS SQUIBB CO (BRM.DE) Stock Price & Overview
FRA:BRM • US1101221083
Current stock price
The current stock price of BRM.DE is 52.49 EUR. Today BRM.DE is up by 1.67%. In the past month the price increased by 3.82%. In the past year, price decreased by -7.03%.
BRM.DE Key Statistics
- Market Cap
- 106.894B
- P/E
- 9.79
- Fwd P/E
- 9.51
- EPS (TTM)
- 5.36
- Dividend Yield
- 4.27%
BRM.DE Stock Performance
BRM.DE Stock Chart
BRM.DE Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to BRM.DE. When comparing the yearly performance of all stocks, BRM.DE turns out to be only a medium performer in the overall market: it outperformed 48.81% of all stocks.
BRM.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to BRM.DE. BRM.DE has an excellent profitability rating, but there are some minor concerns on its financial health.
BRM.DE Earnings
On February 5, 2026 BRM.DE reported an EPS of 1.26 and a revenue of 12.50B. The company beat EPS expectations (11.85% surprise) and beat revenue expectations (0.79% surprise).
BRM.DE Forecast & Estimates
36 analysts have analysed BRM.DE and the average price target is 52.4 EUR. This implies a price decrease of -0.17% is expected in the next year compared to the current price of 52.49.
For the next year, analysts expect an EPS growth of 2.98% and a revenue growth -1.84% for BRM.DE
BRM.DE Groups
Sector & Classification
BRM.DE Financial Highlights
Over the last trailing twelve months BRM.DE reported a non-GAAP Earnings per Share(EPS) of 5.36. The EPS increased by 439.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 14.64% | ||
| ROA | 7.83% | ||
| ROE | 38.19% | ||
| Debt/Equity | 2.33 |
BRM.DE Ownership
BRM.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| SNW | SANOFI | 9.03 | 184.842B | ||
| SAN | SANOFI | 9.07 | 184.793B | ||
| 1SAN | SANOFI | 9.01 | 184.552B | ||
| UCB | UCB SA | 25.07 | 49.581B | ||
| UNC | UCB SA | 24.52 | 49.055B | ||
| 1MRK | MERCK KGAA | 13.41 | 48.217B | ||
| MRK | MERCK KGAA | 13.41 | 47.043B | ||
| BAYN | BAYER AG-REG | 8.59 | 39.385B | ||
| 1BAYN | BAYER AG-REG | 8.36 | 38.422B | ||
| IPN | IPSEN | 12.93 | 12.873B | ||
| TUB | FINANCIERE DE TUBIZE | N/A | 9.614B | ||
| REC | RECORDATI INDUSTRIA CHIMICA | 15.71 | 9.407B | ||
| VIRP | VIRBAC SA | 15.5 | 2.756B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About BRM.DE
Company Profile
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 32,500 full-time employees. The company is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
Company Info
IPO: 1980-03-17
BRISTOL-MYERS SQUIBB CO
Route 206 And Province Line Road
Princeton NEW JERSEY US
Employees: 32500
Phone: 13026587581
BRISTOL-MYERS SQUIBB CO / BRM.DE FAQ
What does BRM do?
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 32,500 full-time employees. The company is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
What is the stock price of BRISTOL-MYERS SQUIBB CO today?
The current stock price of BRM.DE is 52.49 EUR. The price increased by 1.67% in the last trading session.
Does BRISTOL-MYERS SQUIBB CO pay dividends?
BRISTOL-MYERS SQUIBB CO (BRM.DE) has a dividend yield of 4.27%. The yearly dividend amount is currently 2.19.
How is the ChartMill rating for BRISTOL-MYERS SQUIBB CO?
BRM.DE has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
How is the valuation of BRISTOL-MYERS SQUIBB CO (BRM.DE) based on its PE ratio?
The PE ratio for BRISTOL-MYERS SQUIBB CO (BRM.DE) is 9.79. This is based on the reported non-GAAP earnings per share of 5.36 and the current share price of 52.49 EUR.
What is BRISTOL-MYERS SQUIBB CO worth?
BRISTOL-MYERS SQUIBB CO (BRM.DE) has a market capitalization of 106.89B EUR. This makes BRM.DE a Large Cap stock.